Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Hold

Niagen Bioscience (NASDAQ:NAGE) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Other research analysts have also issued reports about the stock. Canaccord Genuity Group decreased their price objective on Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Niagen Bioscience Stock Performance

NASDAQ:NAGE opened at $5.06 on Friday. The stock has a fifty day moving average of $5.74 and a 200 day moving average of $7.10. Niagen Bioscience has a 52-week low of $4.72 and a 52-week high of $14.69. The firm has a market capitalization of $405.20 million, a price-to-earnings ratio of 25.30 and a beta of 2.12.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds have recently bought and sold shares of the company. New York State Teachers Retirement System purchased a new position in Niagen Bioscience in the 4th quarter worth approximately $30,000. Financial Consulate Inc. purchased a new stake in Niagen Bioscience during the 3rd quarter valued at $33,000. State of Alaska Department of Revenue purchased a new stake in Niagen Bioscience during the 3rd quarter valued at $44,000. Ameritas Investment Partners Inc. bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth $45,000. Finally, North Star Investment Management Corp. bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth $47,000. Institutional investors own 15.41% of the company’s stock.

More Niagen Bioscience News

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 beat and profit strength — Niagen reported quarterly EPS that topped estimates and stronger-than-expected revenue; media coverage notes the company doubled annual profit and management signaled an acquisition hunt and expansion into GLP‑1-style products, which drove significant after-hours buying interest. Niagen Bioscience Doubles Annual Profit (MSN)
• Positive Sentiment: Quarterly beat confirmed by multiple outlets — Coverage and transcripts highlight strong revenue growth and an EPS beat for Q4, supporting the narrative of improving operations and profitability. NAGE Tops Q4 Earnings (Zacks)
• Neutral Sentiment: Price target tweak but rating intact — Canaccord trimmed its price target from $14 to $13 while maintaining a “buy” rating, signaling continued analyst conviction but a more conservative valuation. Canaccord Price Target Update (Benzinga)
• Neutral Sentiment: HC Wainwright updated multi-quarter and FY2027 EPS models — the firm published a full set of quarterly and FY2027 estimates (FY2027 ~$0.37 EPS), providing a new baseline for investor expectations (mixed across quarters).
• Negative Sentiment: Revenue guidance below street estimates — Niagen issued FY2026 revenue guidance of $142.4M–$148.8M versus a consensus around $153.3M, which reduces near-term top-line visibility and likely pressured the share price despite the quarterly beat. Valuation After New 2026 Guidance (Yahoo)
• Negative Sentiment: Analyst cuts to FY2026 and near-term quarters — HC Wainwright reduced FY2026 EPS (from $0.38 to $0.33) and cut Q2 2026 materially, which may weigh on sentiment as models are reset lower despite stronger Q4 results.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.